EA202190089A1 - SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS - Google Patents

SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS

Info

Publication number
EA202190089A1
EA202190089A1 EA202190089A EA202190089A EA202190089A1 EA 202190089 A1 EA202190089 A1 EA 202190089A1 EA 202190089 A EA202190089 A EA 202190089A EA 202190089 A EA202190089 A EA 202190089A EA 202190089 A1 EA202190089 A1 EA 202190089A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen binding
psma
binding molecules
bodies
bispecific antigen
Prior art date
Application number
EA202190089A
Other languages
Russian (ru)
Inventor
Эндрю Дж. МЕРФИ
Димитрис Скокос
Джейнелл Уэйт
Эрика Уллман
Айнур Херманн
Эрик Смит
Лорик Абер
Джордж Д. Янкопулос
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2019/038460 external-priority patent/WO2019246514A1/en
Publication of EA202190089A1 publication Critical patent/EA202190089A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к биспецифичным антигенсвязывающим молекулам, содержащим первый антигенсвязывающий домен, который специфично связывает CD28 человека, и вторую антигенсвязывающую молекулу, которая специфично связывает PSMA человека. В отдельных вариантах осуществления биспецифичные антигенсвязывающие молекулы согласно настоящему изобретению способны ингибировать рост опухолей, экспрессирующих PSMA, таких как опухоли предстательной железы. Антитела и биспецифичные антигенсвязывающие молекулы согласно изобретению эффективны для лечения заболеваний и расстройств, при которых желателен и/или терапевтически эффективен повышенный или индуцированный нацеленный иммунный ответ.The present invention relates to bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human CD28 and a second antigen binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen binding molecules of the present invention are capable of inhibiting the growth of PSMA expressing tumors, such as prostate tumors. The antibodies and bispecific antigen binding molecules of the invention are effective in the treatment of diseases and disorders in which an increased or induced targeted immune response is desired and / or therapeutically effective.

EA202190089A 2019-03-08 2019-06-21 SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS EA202190089A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815878P 2019-03-08 2019-03-08
PCT/US2019/038460 WO2019246514A1 (en) 2018-06-21 2019-06-21 Bispecific anti-psma x anti-cd28 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202190089A1 true EA202190089A1 (en) 2021-03-22

Family

ID=75262254

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190089A EA202190089A1 (en) 2019-03-08 2019-06-21 SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS

Country Status (1)

Country Link
EA (1) EA202190089A1 (en)

Similar Documents

Publication Publication Date Title
EA202191580A1 (en) SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION
PH12020552116A1 (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
PH12021551238A1 (en) Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof
EA201890368A1 (en) ANTIBODIES AGAINST PSMA, BISPECIFIC ANTIGENSELATING MOLECULES THAT BIND PSMA AND CD3 AND THEIR APPLICATION
EA201890785A1 (en) OPTIMIZED BISPECIFIC ANTI-CD3 ANTIBODIES AND THEIR APPLICATION
EA201990781A1 (en) ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION
EA201590613A1 (en) ANTIBODIES AGAINST CD3, BISPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO CD3 AND CD20, AND THEIR APPLICATIONS
EA201691858A1 (en) ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS
EA202190315A1 (en) CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO BCMA AND THEIR APPLICATION
EA201992402A1 (en) ANTIBODIES AGAINST ILT4 AND ANTIGEN-BINDING FRAGMENTS
EA201491686A1 (en) MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND THEIR APPLICATIONS
BR112022009317A2 (en) BIPARATOPIC CD73 ANTIBODIES
MX2021015271A (en) Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation.
EA202190089A1 (en) SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS
EA202191677A1 (en) SPECIFIC ANTI-MUC16 X ANTI-CD28 ANTI-BODIES AND VARIANTS OF THEIR APPLICATION
EA202190601A1 (en) ANTI-Fc ANTIBODIES EPSILON-R1 ALPHA (FCER1A), BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING FCΕR1Α AND CD3 AND THEIR APPLICATION
EA201991227A1 (en) ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20
EA202090303A3 (en) ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS
EA202190314A1 (en) BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND METHODS OF THEIR APPLICATION
EA202092279A1 (en) ANTIBODIES TO MICA AND / OR MICB AND THEIR APPLICATION
EA202092672A1 (en) ANTIBODIES AGAINST DLL3 AND THEIR APPLICATION
EA201992312A1 (en) SPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF APPLICATION
EA201992324A1 (en) ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION
EA201990779A1 (en) SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND CONJUGATES ANTI-MUC16-MEDICINE
EA202192306A3 (en) POLYSPECIFIC ANTIGEN-BINDING MOLECULES AND THEIR APPLICATIONS